Ceritinib
Buy high quality Ceritinib Impurities from Chemicea Pharma. Chemicea Pharma is one of the
leading manufacturer and exporter of Ceritinib impurities.
We synthesize Ceritinib Degradation Impurities, Ceritinib Process
Impurities, Ceritinib Potential Impurities, Ceritinib USP Related
Compound, Ceritinib N-Nitroso impurities, Ceritinib nitrosamine impurities
etc.
Pharmaceutical Reference Standards
Ceritinib
| CAT. No. | CP-C139000 |
|---|---|
| CAS. No. | 1032900-25-6 |
| Mol. F. | C28H36ClN5O3S |
| Mol. Wt. | 558.14 |
| Stock Status: | Custom Synthesis |
N-Nitroso Ceritinib
| CAT. No. | CP-C139001 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C28H35ClN6O4S |
| Mol. Wt. | 587.14 |
| Stock Status: | Please Enquire |
N-Nitroso Ceritinib Impurity 1
| CAT. No. | CP-C139002 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C28H34ClN7O5S |
| Mol. Wt. | 616.13 |
| Stock Status: | Please Enquire |
N-Nitroso Ceritinib Impurity 2
| CAT. No. | CP-C139003 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C28H35ClN6O4S |
| Mol. Wt. | 587.14 |
| Stock Status: | Please Enquire |
N-Nitroso Ceritinib Impurity 3
| CAT. No. | CP-C139004 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C28H34ClN7O5S |
| Mol. Wt. | 616.13 |
| Stock Status: | Please Enquire |
2-Chloro-4-fluoro-5-nitrotoluene
| CAT. No. | CP-C139005 |
|---|---|
| CAS. No. | 112108-73-3 |
| Mol. F. | C7H5ClFNO2 |
| Mol. Wt. | 189.57 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 8
| CAT. No. | CP-C139006 |
|---|---|
| CAS. No. | 1032903-50-6 |
| Mol. F. | C10H12ClNO3 |
| Mol. Wt. | 229.66 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 9
| CAT. No. | CP-C139007 |
|---|---|
| CAS. No. | 100777-46-6 |
| Mol. F. | C8H8ClNO3 |
| Mol. Wt. | 201.61 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 10
| CAT. No. | CP-C139008 |
|---|---|
| CAS. No. | 64695-96-1 |
| Mol. F. | C7H7BrFNO2 |
| Mol. Wt. | 236.04 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 11
| CAT. No. | CP-C139009 |
|---|---|
| CAS. No. | 761440-16-8 |
| Mol. F. | C13H13Cl2N3O2S |
| Mol. Wt. | 346.23 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 12
| CAT. No. | CP-C139010 |
|---|---|
| CAS. No. | 761440-17-9 |
| Mol. F. | C12H11Cl2N3O2S |
| Mol. Wt. | 332.2 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 15
| CAT. No. | CP-C139011 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C24H28ClN5O2S |
| Mol. Wt. | 485.17 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 16
| CAT. No. | CP-C139012 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C26H33N5O3S |
| Mol. Wt. | 495.23 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 17
| CAT. No. | CP-C139013 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C25H31ClN6O2S |
| Mol. Wt. | 514.19 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 18
| CAT. No. | CP-C139014 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C26H34N6O2S |
| Mol. Wt. | 494.25 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 19
| CAT. No. | CP-C139015 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C24H30ClN7O2S |
| Mol. Wt. | 515.19 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 20
| CAT. No. | CP-C139016 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C25H32ClN7O2S |
| Mol. Wt. | 529.20 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 21
| CAT. No. | CP-C139017 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C26H35N7O2S |
| Mol. Wt. | 509.26 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 22
| CAT. No. | CP-C139018 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C25H33ClN8O2S |
| Mol. Wt. | 544.21 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 23
| CAT. No. | CP-C139019 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C27H37N8O2S |
| Mol. Wt. | 537.28 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 24
| CAT. No. | CP-C139020 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C26H33ClN6O2S |
| Mol. Wt. | 528.21 |
| Stock Status: | Custom Synthesis |
Ceritinib Impurity 25
| CAT. No. | CP-C139021 |
|---|---|
| CAS. No. | NA |
| Mol. F. | C24H29ClN6O3S |
| Mol. Wt. | 516.17 |
| Stock Status: | Custom Synthesis |
© 2024 Chemicea Limited | All Rights Reserved.
